Felix Kaul

1.3k total citations
20 papers, 981 citations indexed

About

Felix Kaul is a scholar working on Oncology, Epidemiology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Felix Kaul has authored 20 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 10 papers in Epidemiology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Felix Kaul's work include Neuroendocrine Tumor Research Advances (10 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Lung Cancer Research Studies (5 papers). Felix Kaul is often cited by papers focused on Neuroendocrine Tumor Research Advances (10 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Lung Cancer Research Studies (5 papers). Felix Kaul collaborates with scholars based in Switzerland, Germany and United States. Felix Kaul's co-authors include Jürgen A. Kleinschmidt, Martin Trepel, Oliver J. Müller, Damian Wild, Matthew D. Weitzman, Renata Pasqualini, Wadih Arap, Melpomeni Fani, Guillaume Nicolas and Emanuel Christ and has published in prestigious journals such as Blood, Nature Biotechnology and Journal of Nuclear Medicine.

In The Last Decade

Felix Kaul

18 papers receiving 968 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Felix Kaul Switzerland	9	464	456	331	298	248	20	981
Anthony K. Shum United States	15	52 0.1×	70 0.2×	304 0.9×	133 0.4×	65 0.3×	27	955
Fabio Cappuccini United States	17	300 0.6×	225 0.5×	210 0.6×	43 0.1×	35 0.1×	36	843
Sophie Sibéril France	14	154 0.3×	119 0.3×	232 0.7×	61 0.2×	321 1.3×	31	930
Isabelle Isnardi United States	10	70 0.2×	69 0.2×	186 0.6×	232 0.8×	135 0.5×	11	1.0k
К. И. Киргизов Russia	11	311 0.7×	74 0.2×	162 0.5×	67 0.2×	35 0.1×	83	982
Nicholas Willcox United Kingdom	21	126 0.3×	43 0.1×	206 0.6×	122 0.4×	211 0.9×	43	1.4k
Yumi Honda Japan	16	275 0.6×	203 0.4×	158 0.5×	45 0.2×	44 0.2×	62	758
Issam Al‐Bozom Qatar	15	154 0.3×	104 0.2×	202 0.6×	39 0.1×	31 0.1×	57	760
Madoka Furukawa Japan	15	216 0.5×	89 0.2×	151 0.5×	56 0.2×	72 0.3×	53	696
Nicolas Gestermann France	12	243 0.5×	74 0.2×	286 0.9×	113 0.4×	28 0.1×	12	1.0k

Countries citing papers authored by Felix Kaul

Since Specialization

Citations

This map shows the geographic impact of Felix Kaul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Kaul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Kaul more than expected).

Fields of papers citing papers by Felix Kaul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Kaul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Kaul. The network helps show where Felix Kaul may publish in the future.

Co-authorship network of co-authors of Felix Kaul

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Kaul. A scholar is included among the top collaborators of Felix Kaul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Kaul. Felix Kaul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nicolas, Guillaume, Lisa McDougall, Felix Kaul, et al.. (2025). First-in-human administration of [61Cu]Cu-NODAGA-LM3 and head-to-head comparison with [68Ga]Ga-DOTA-TOC PET/CT as part of the phase I/II COPPER PET in NET study. European Journal of Nuclear Medicine and Molecular Imaging. 53(2). 710–712.

Rottenburger, Christof, Michael Hentschel, Markus Fürstner, et al.. (2024). In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study. EJNMMI Research. 14(1). 37–37. 6 indexed citations

Winkel, David, Felix Kaul, Theo Demerath, et al.. (2023). Estimation of differential renal function on routine abdominal imaging employing compressed-sensed contrast-enhanced MR: a feasibility study referenced against dynamic renal scintigraphy in patients with deteriorating renal retention parameters. Abdominal Radiology. 48(4). 1329–1339. 1 indexed citations

Schwab, Fabienne D., Felix Kaul, James D. Geiger, et al.. (2023). Contralateral lymph node metastasis in recurrent ipsilateral breast cancer with Lynch syndrome: a locoregional event. World Journal of Surgical Oncology. 21(1). 40–40.

Lunger, Alexander, Rik Osinga, Franziska Saxer, et al.. (2021). Case Report: Reconstruction of a Large Maxillary Defect With an Engineered, Vascularized, Prefabricated Bone Graft. Frontiers in Oncology. 11. 775136–775136. 9 indexed citations

Braun, Martin, Felix Kaul, Federico Caobelli, et al.. (2021). Accuracy comparison of various quantitative [99mTc]Tc-DPD SPECT/CT reconstruction techniques in patients with symptomatic hip and knee joint prostheses. EJNMMI Research. 11(1). 60–60. 4 indexed citations

Kobayashi, Noritoshi, Damian Wild, Felix Kaul, et al.. (2021). Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. Journal of Hepato-Biliary-Pancreatic Sciences. 28(9). 727–739. 5 indexed citations

Rottenburger, Christof, Guillaume Nicolas, Lisa McDougall, et al.. (2021). The CCK-2 receptor agonist Lu-177-PP-F11N for PRRT of medullary thyroid cancer – Recent results of the phase 1 “LUMED” Study. Nuklearmedizin - NuclearMedicine. 2 indexed citations

Antwi, Kwadwo, Matthias Hepprich, Jean Claude Reubi, et al.. (2020). Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging. Clinical Nuclear Medicine. 45(9). e386–e392. 15 indexed citations

10.

Antwi, Kwadwo, Matthias Hepprich, Jean Claude Reubi, et al.. (2020). Pitfalls in the Detection of Insulinomas with GLP-1R Imaging. 61. 566–566. 1 indexed citations

11.

Rottenburger, Christof, Guillaume Nicolas, Lisa McDougall, et al.. (2019). Evaluation of the CCK-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - final Results of the phase 0 'Lumed' Study. Endocrine Abstracts. 3 indexed citations

12.

Rottenburger, Christof, Guillaume Nicolas, Lisa McDougall, et al.. (2019). Cholecystokinin 2 Receptor Agonist ¹⁷⁷Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. Journal of Nuclear Medicine. 61(4). 520–526. 67 indexed citations

13.

Antwi, Kwadwo, Melpomeni Fani, Tobias Heye, et al.. (2018). Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. European Journal of Nuclear Medicine and Molecular Imaging. 45(13). 2318–2327. 97 indexed citations

14.

Nicolas, Guillaume, N. Schreiter, Felix Kaul, et al.. (2017). Sensitivity Comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study. Journal of Nuclear Medicine. 59(6). 915–921. 129 indexed citations

15.

Nicolas, Guillaume, N. Schreiter, Felix Kaul, et al.. (2016). PET/CT with the somatostatin receptor antagonist 68Ga-OPS202 is twice as accurate as with the agonist 68Ga-DOTATOC for detecting liver metastases: Results of a phase 1/2 study in gastroenteropancreatic NET patients.. 57. 154–154. 5 indexed citations

16.

Nicolas, Guillaume, et al.. (2015). First clinical data on 68Ga-labeled somatostatin receptor antagonists: a phase I/II study comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT.. 56. 266–266. 3 indexed citations

17.

Wild, Damian, Melpomeni Fani, Richard Fischer, et al.. (2014). Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. Journal of Nuclear Medicine. 55(8). 1248–1252. 196 indexed citations

18.

Hoelzer, Dieter, Felix Kaul, Nadja Jaekel, et al.. (2010). Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003. Blood. 116(21). 170–170. 67 indexed citations

19.

Michelfelder, Stefan, Mi‐Kyung Lee, Felix Kaul, et al.. (2007). Vectors selected from adeno-associated viral display peptide libraries for leukemia cell–targeted cytotoxic gene therapy. Experimental Hematology. 35(12). 1766–1776. 54 indexed citations

20.

Müller, Oliver J., Felix Kaul, Matthew D. Weitzman, et al.. (2003). Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nature Biotechnology. 21(9). 1040–1046. 317 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact